Ivosidenib for Brain Cancer

This trial examines how the drug ivosidenib works for individuals with certain types of cancer and specific liver or kidney issues. The trial aims to assess how the body processes the drug, its effects, and its safety and tolerability. Participants will join different groups based on their liver or kidney function. Candidates may qualify if they have cancer with an IDH1 mutation and either liver or kidney problems, or if their liver and kidney functions are normal. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this potentially groundbreaking therapy.

The trial requires that you stop taking certain medications, especially those that prolong the QT interval or are strong CYP3A4 inducers or substrates. You must have a washout period (time without taking these medications) of at least 5 half-lives before starting the trial and cannot take them during the study.

Research has shown that ivosidenib generally has a manageable safety profile. In one study, about 19.7% of participants experienced serious side effects, but only 3% were directly related to the treatment. Another study found that ivosidenib was usually well-tolerated and helped control tumor growth in patients with advanced glioma, a type of brain tumor. Overall, these findings suggest that while some risks exist, patients generally tolerate ivosidenib well.¹²³⁴⁵

Ivosidenib is unique because it specifically targets a protein called IDH1, which is mutated in some brain cancers. Unlike traditional chemotherapy, which attacks all rapidly dividing cells, ivosidenib works by inhibiting the abnormal IDH1 enzyme, potentially stopping cancer cell growth with fewer side effects. Researchers are excited about ivosidenib because it offers a more targeted approach, which might translate to better outcomes and improved quality of life for patients with brain cancer.

Research has shown that ivosidenib may help treat certain brain cancers. It works well for patients with non-enhancing gliomas, which are slow-growing brain tumors that don't appear on scans after a special dye is used. Studies found that 85.7% of these patients had stable disease, meaning their cancer did not worsen. However, it was less effective for those with enhancing gliomas, with only 45.2% achieving stable disease. This suggests that ivosidenib might be more beneficial for certain types of brain tumors, especially those that grow more slowly. Participants in this trial will be grouped based on hepatic and renal function to assess the treatment's effectiveness across different health conditions.¹²⁴⁶⁷